×
About 8,360 results

ALLMedicine™ Glioblastoma Multiforme Center

Research & Reviews  2,723 results

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
https://clinicaltrials.gov/ct2/show/NCT03538587

Jun 24th, 2022 - Background Children and young adults diagnosed with a high-grade or high-risk cancer (e.g., diffuse intrinsic pontine glioma, glioblastoma multiforme, relapsed-refractory leukemia, refractory metastatic sarcomas) face a poor prognosis given limite...

A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients wit...
https://doi.org/10.3390/curroncol29060345
Current Oncology (Toronto, Ont.); Bafiti V, Ouzounis S et. al.

Jun 24th, 2022 - Malignant gliomas constitute a complex disease phenotype that demands optimum decision-making as they are highly heterogeneous. Such inter-individual variability also renders optimum patient stratification extremely difficult. microRNA (hsa-miR-20...

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT00083512

Jun 24th, 2022 - BACKGROUND Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary VEGF and MMP level at the one month follow-up time point compared to the last on-treatment time point collection may be predictive of tumor recurrenc...

Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
https://doi.org/10.1093/neuonc/noac157
Neuro-oncology Chen X, Niu W et. al.

Jun 22nd, 2022 - Glioblastoma multiforme and other solid malignancies are heterogeneous, containing subpopulations of tumor cells that exhibit stem characteristics. Oct4, also known as POU5F1, is a key transcription factor in the self-renewal, proliferation, and d...

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
https://clinicaltrials.gov/ct2/show/NCT00479765

Jun 22nd, 2022 - This study is for patients with recurrent glioblastoma multiforme. Because most recurrences are in the area of the original resection, local delivery of a chemotherapeutic agent may prevent or delay additional recurrences. Paclitaxel has demonstra...

see more →

Guidelines  1 results

The role of radiotherapy in the management of progressive glioblastoma : a systematic r...
https://doi.org/10.1007/s11060-013-1337-6
Journal of Neuro-oncology; Ryu S, Buatti JM et. al.

Apr 15th, 2014 - Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiati...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  487 results

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
https://clinicaltrials.gov/ct2/show/NCT03538587

Jun 24th, 2022 - Background Children and young adults diagnosed with a high-grade or high-risk cancer (e.g., diffuse intrinsic pontine glioma, glioblastoma multiforme, relapsed-refractory leukemia, refractory metastatic sarcomas) face a poor prognosis given limite...

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT00083512

Jun 24th, 2022 - BACKGROUND Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary VEGF and MMP level at the one month follow-up time point compared to the last on-treatment time point collection may be predictive of tumor recurrenc...

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
https://clinicaltrials.gov/ct2/show/NCT00479765

Jun 22nd, 2022 - This study is for patients with recurrent glioblastoma multiforme. Because most recurrences are in the area of the original resection, local delivery of a chemotherapeutic agent may prevent or delay additional recurrences. Paclitaxel has demonstra...

Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
https://clinicaltrials.gov/ct2/show/NCT04222309

Jun 22nd, 2022 - Laparoscopically harvested omental free flaps are commonly used to fill surgical cavities after resection of head and neck cancers. The investigators hypothesize that a laparoscopically harvested omental free flap in our patients with resected rec...

Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT05423210

Jun 21st, 2022 - This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition t...

see more →

News  127 results

Management of Progressive Glioblastoma Clinical Practice Guidelines (CNS, 2022)
https://www.medscape.com/viewarticle/974543

May 31st, 2022 - Updated guidelines for the management of progressive glioblastoma were published in May 2022 by the Congress of Neurological Surgeons (CNS) in Neurosurgery.[1] Imaging Gadolinium contrast-enhanced magnetic resonance imaging (MRI) is recommended fo...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
https://www.onclive.com/view/fda-grants-fast-track-designation-to-cynk-101-for-her2-gastric-gej-cancers

Jan 19th, 2022 - The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab (Herceptin), and pembrolizumab (Keytruda) for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ)...

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma
https://www.onclive.com/view/fda-grants-fast-track-designation-to-st101-for-recurrent-glioblastoma

Dec 6th, 2021 - The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma, according to an announcement from Sapience Therapeutics, Inc., the drug developer.1 The decision is ...

Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging
https://www.onclive.com/view/advanced-3d-mri-technology-marks-a-leap-forward-in-glioblastoma-imaging

Oct 6th, 2021 - Hui-Kuo Shu, MD, PhD Associate Professor Although advances have been made in imaging techniques for patients with glioblastoma multiforme (GBM), new tools are needed to supplement standard imaging sequences. Researchers at the Winship Cancer...

see more →

Patient Education  1 results see all →